

Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2021 ended December 31, 2021.

Recent Highlights

- Recorded worldwide revenue of \$13.7 million in the fourth quarter and \$48.4 million for the full year of 2021, representing 39% and 48% increases respectively, over the corresponding periods of 2020
- Realized gross margin of 74.8% in the fourth quarter and 73.6% for the full year of 2021, as compared to 72.0% and 64.8% respectively in the corresponding periods of 2020
- Expanded base of U.S. treatment centers for Zephyr Valves to 214 representing 45% growth since the start of 2021
- Submitted regulatory filing seeking Zephyr Valve approval in Japan in December 2021

"I'm extremely proud of what the team accomplished in 2021. Despite COVID headwinds, we ended the year with three consecutive quarters of record worldwide sales and a significant expansion of our base of treatment centers. We also made progress toward geographic expansion into Japan and the clinical development of AeriSeal," said Glen French, President & Chief Executive Officer. "We look forward to continuing to build on our strong foundation for growth through 2022, particularly in the back half of the year."

Fourth Quarter 2021 Financial Results

Total worldwide revenue in the fourth quarter of 2021 was \$13.7 million, a 39% increase from \$9.8 million in the fourth quarter of 2020 and an increase of 40% on a constant currency basis. U.S. revenue was \$7.3 million, a 49% increase from the fourth quarter of 2020. International revenue was \$6.4 million, a 30% increase compared to the fourth quarter of 2020, and a 31% increase on a constant currency basis. The increase in revenue reflects continued strong commercial momentum and growth of Zephyr Valve procedure volumes.

Gross profit in the fourth quarter of 2021 was \$10.3 million, compared to \$7.1 million for the fourth quarter of 2020. Gross margin for the fourth quarter of 2021 was 74.8%, up from 72.0% for the same period in 2020. The improvement in gross margin primarily reflects production efficiencies.

Operating expenses in the fourth quarter of 2021 were \$22.6 million, compared to \$16.4 million for the fourth quarter of 2020, representing an increase of 38%. The increase in operating expenses was driven primarily by investments in our commercial and research and development functions, stock-based compensation, and expenses associated with the scaling of our general and administrative infrastructure.

Net loss in the fourth quarter of 2021 was \$13.0 million, or \$0.35 per share, compared to a net loss of \$9.3 million, or \$0.27 per share, for the same period in 2020.

Full Year 2021 Financial Results

Total worldwide revenue for the full year of 2021 was \$48.4 million, a 48% increase from \$32.7 million for the full year of 2020 and an increase of 45% on a constant currency basis. U.S. revenue was \$25.0 million, a 54% increase from \$16.2 million for the full year of 2020. International revenue was \$23.4 million, a 42% increase from \$16.5 million for the full year of 2020, and a 35% increase on a constant currency basis. The increase in revenue reflects continued strong commercial momentum and growth of Zephyr Valve procedure volumes.

Gross profit for the full year of 2021 was \$35.6 million, compared to \$21.2 million for the full year of 2020. Gross margin for the full year of 2021 was 73.6%, up from 64.8% for the full year of 2020. The improvement in gross margin primarily reflects production efficiencies as well as a slowdown in production during the first months of the pandemic in 2020.

Operating expenses for the full year of 2021 were \$82.9 million, compared to \$53.5 million for the full year of 2020, representing an increase of 55%. The increase in operating expenses was driven primarily by investments in our commercial and research and development functions, stock-based compensation, expenses associated with operating as a public company, and expenses related to the scaling of our general and administrative infrastructure.

Net loss for the full year of 2021 was \$48.7 million, or \$1.35 per share, compared to a net loss of \$32.2 million, or \$3.16 per share per share, for the same period in 2020.

Cash, cash equivalents, and marketable securities totaled \$191.0 million as of December 31, 2021, compared to \$231.6 million as of December 31, 2020.

Full Year & First Quarter 2022 Financial Guidance

Pulmonx expects revenue for the full year 2022 to be in the range of \$55 million to \$60 million. Taking into account the ongoing impact of COVID-19, Pulmonx expects revenue for the first quarter 2022 to be in the range of \$9 million to \$10 million.

The Company expects total operating expenses for the full year 2022 to fall within the range of \$100 million to \$105 million inclusive of stock-based

compensation.

Webcast and Conference Call Details

Pulmonx will host a conference call today, February 23, 2022, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and to discuss its full year and first quarter 2022 financial guidance. The dial-in numbers are (833) 614-1518 for domestic callers and (270) 823-1072 for international callers. The conference ID is 8494407. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

Pulmonx has presented constant currency percentage change in revenues, a non-GAAP financial measure, in this press release. Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Reconciliation of this non-GAAP financial measure to the most comparable GAAP measure is set forth in the tables below.

Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors' ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx's historical operating results. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx's business.

This non-GAAP financial measure should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on the Company and its operations, a recovery in the number of procedures performed, and the Company's possible or assumed future results of operations, including descriptions of the Company's revenues, gross margin, profitability, guidance for Q-1 and full year 2022, commercial momentum, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx's public filings with the Securities and Exchange Commission ("SEC"), including the Quarterly Report on Form 10-Q filed with the SEC on November 9, 2021, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company's business.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

AeriSeal®, Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Investor Contact

Brian Johnston Gilmartin Group investors@pulmonx.com

Pulmonx Corporation Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)

	Th:	Three Months Ended December 31,			Twelve Months Ended December 31,			
		2021		2020		2021		2020
Revenue	\$	13,708	\$	9,830	\$	48,416	\$	32,733
Cost of goods sold		3,457		2,752		12,786		11,531
Gross profit		10,251		7,078		35,630		21,202
Operating expenses								
Research and development		3,708		2,472		13,063		7,460
Selling, general and administrative		18,909		13,960		69,871		46,074
Total operating expenses		22,617		16,432		82,934		53,534

Loss from operations	(12,366)	(9,354)	(47,304)	(32,332)
Interest income	94	115	400	213
Interest expense	(199)	(267)	(829)	(3,181)
Other income (expense), net	 (383)	230	(585)	 3,282
Net loss before tax	(12,854)	(9,276)	 (48,318)	(32,018)
Income tax expense	 152	21	343	 213
Net loss	\$ (13,006)	\$ (9,297)	\$ (48,661)	\$ (32,231)
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.35)	\$ (0.27)	\$ (1.35)	\$ (3.16)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	36,637,399	33,915,893	36,129,409	10,184,841

Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands) (Unaudited)

Assets Current assets 231 232 232 232 2428 100 232 2428 100 2428 100 2428 100 2428 100 2428 100 2428 100 2428 100 2429 100 249,088 3,228 100 249,088 100 249,088 100 249,088 100 249,088 100 249,088 100 100 249,088 100 249,088 100 100 249,088 100 100 249,088 100 100 249,088 100 100 249,088 100 100 249,088 100 100 200 249,088 100 100 200 200 200 200		December 31, 2021	December 31, 2020		
Cash and cash equivalents \$ 148,480 \$ 231,561 Restricted cash 31,561 - Short-term marketable securities 31,561 - Accounts receivable, net 6,562 4,228 Inventory 16,285 10,741 Prepaid expenses and other current assets 4,883 3,228 Total current assets 208,002 249,989 Long-term marketable securities 10,941 - Long-term marketable securities 10,941 - Long-term marketable securities 4,814 1,474 Goodwill 2,233 2,333 Intagnitie assets, net 277 40 Right of use assets 8,075 8,765 Other long-term assets 8,075 8,976 Total assets 1,252 8,233 Accounts paysets 1,582 8,273 Accounts payable 1,152 9,242 Accounts payable 1,152 1,252 Deferred revenue 1,23 2,238 Total current labilities 1,	Assets				
Restricted cash 315 231 Short-term marketable securities 3.55c 4.228 Accounts receivable, net 6.562 4.228 Inventory 16.285 10.741 Prepaid expenses and other current assets 208,002 249.988 Cola current assets 208,002 249.988 Long-term marketable securities 10.941 1.74 Property and equipment, net 4.813 1.74 Goodwill 2.33 2.33 Intal aguity of use assets 277 4.00 Right of use assets 731 5.0 Other long-term assets 731 5.0 Coll train assets 731 5.0 Total assets 731 5.0 Labilities 731 5.0 Current liabilities 1,562 1,472 Accounts payable 1,172 4.0 Accounts payable 1,47 9.4 Deferred revenue 163 7.1 Credit agreement, current 2,20 1.2,23	Current assets				
Short-term marketable securities 31,561 4.228 Accounts receivable, net Inventory 15,285 1,0741 Prepaid expenses and other current assets 4,883 3,228 Total current assets 208,002 249,988 Long-term marketable securities 10,941 1,474 Brobert marketable securities 1,941 1,474 Goodwill 2,333 2,333 Constraint assets 8,075 8,976 Other long-term assets 7,731 5,06 Other long-term assets 7,31 5,06 Total assets 8,075 8,976 Urrent liabilities 3,1561 9,175 Accounts payable 1,1582 1,472 Accounts payable 1,1582 1,472 Accounts payable 1,1582 1,472 Accounts payable 1,1582 1,472 Accurent liabilities 2,201 2,233 Current lease liabilities 2,201 2,231 Current lease liabilities 6,844 7,618 Cong-term lease	Cash and cash equivalents	\$ 148,48	0 \$ 231,561		
Accounts receivable, net Inventory 6,562 4,288 Inventory 16,285 10,741 Prepaid expenses and other current assets 4,883 3,228 Ital current assets 208,002 249,898 Long-term marketable securities 10,941 Property and equipment, net 4,814 1,747 Goodwill 2,333 2,333 Intangible assets, net 277 400 Right of use assets 8,075 8,766 Other long-term assets 731 536 Total assets \$ 235,173 \$ 263,708 User Italibilities \$ 1,582 \$ 1,472 Accounts payable \$ 1,582 \$ 1,472 Accounts payable \$ 1,582 \$ 1,472 Account labilities \$ 1,582 \$ 1,472 Account labelities \$ 1,582 \$ 1,472 Criedit agreement, current \$ 1,593 \$ 2,203 Current lasse liabilities \$ 2,201 \$ 2,203 Deferred tax liability \$ 1,505 \$ 5,64 Congl-t	Restricted cash	23	1 231		
Inventory 16,285 10,741 Prepaid expenses and other current assets 208,002 249,898 Long-term marketable securities 10,941 - Property and equipment, net 4,814 1,474 Goodwill 2,333 2,333 Intangible assets, net 8,075 8,976 Other long-term assets 8,075 8,976 Other long-term assets 3,351,73 263,700 Other long-term tilabilities 1,352 8,755 Accounts payable 1,352 8,651 Accounts payable 1,47 94 Deferred revenue 1147 94 Deferred revenue 113,366 8,651 Current lassi liabilities 2,201 2,233 Total current liabilities 3,7 62 Total current liabilities 6,844 7,618 Ceffed targeement </td <td>Short-term marketable securities</td> <td>31,56</td> <td>1 -</td>	Short-term marketable securities	31,56	1 -		
Prepaid expenses and other current assets 4,883 3,228 Total current assets 208,002 249,989 Long-term marketable securities 10,941 1,474 Property and equipment, net 4,814 1,474 Godwill 2,333 2,333 Intagible assets, net 8,075 8,076 Right of use assets 3,011 50 Other long-term assets 731 53 Total assets 2,351,73 263,700 Usbrittles and Stockholders' Equity 8,075 8,076 Current liabilities 13,366 8,651 Income taxes payable 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 7,1 Credit agreement, current 91 2,238 Total current liabilities 17,550 12,258 Total current liabilities 4,55 5,64 Credit agreement 4,55 5,64 Credit agreement 6,844 7,618 Credit agreement 6,844	Accounts receivable, net	6,56	2 4,228		
Total current assets 208,002 249,898 Long-term marketable securities 10,941 - 1,474 Froperty and equipment, net 4,814 1,474 Goodwill 2,333 2,333 Intargible assets, net 2,77 400 Right of use assets 8,075 8,976 Other long-term assets 731 536 Total assets 235,173 \$ 263,708 Liabilities and Stockholders' Equity Current liabilities 1,582 \$ 1,572 Accorust payable 1,582 \$ 1,472 Accorust payable 14,7 94 Deferred revenue 11,752 1,472 Credit agreement, current 91 - Credit agreement, current 91 - Total current liabilities 37 6 Total current lease liabilities 6,844 7,618 Credit agreement 45 564 Credit agreement 45 564 Credit agreement 1,761 6,844	Inventory	16,28	5 10,741		
Long-term marketable securities 10,941	Prepaid expenses and other current assets	4,88	3 3,228		
Property and equipment, net 4,814 1,474 Goodwill 2,333 2,333 Intangible assets, net 277 400 Right of use assets 8,075 8,976 Other long-term assets 731 536 Total assets 235,173 263,708 Liabilities and Stockholders' Equity Current liabilities Accorust payable 13,366 8,651 Income taxes payable 147 94 Deferred revenue 91 - Current lease liabilities 2,201 2,238 Total current liabilities 37 6 Current lease liabilities 17,550 12,526 Deferred tax liabilities 6,844 7,618 Cong-term lease liabilities 6,844 7,618 Cong-term liabilities 16,869 16,804 Cong-term liabilities 45,84 3,574 Total liabilities 16,804 7,618 Cong-term liabilities 48,285 6,844 Total liabilities	Total current assets	208,00	2 249,989		
Godwill 2,333 2,333 Intangible assets, net 207 400 Right of use assets 8,075 8,976 Other long-term assets 731 536 Total assets 235,173 263,708 Liabilities and Stockholders' Equity We remaid liabilities Accounts payable 1,582 1,672 8,651 Income taxes payable 147 94 94 94 1,61 94 1,61 1,61 1,61 1,61 1,62 1,61 1,62 1,61 1,62 1,61 1,61 1,61 4,64 1,61	Long-term marketable securities	10,94	1 -		
Intangible assets, net 277 400 Right of use assets 8,075 8,976 Other long-term assets 731 536 Total assets 235,173 263,708 Liabilities and Stockholders' Equity 8 235,173 263,708 Liabilities 8 1,582 \$ 1,472 Accounts payable \$ 1,582 \$ 1,472 Accoul liabilities 13,366 8,651 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 2 <td>Property and equipment, net</td> <td>4,81</td> <td>4 1,474</td>	Property and equipment, net	4,81	4 1,474		
Right of use assets 8,075 8,976 Other long-term assets 731 536 Total assets \$ 235,173 \$ 263,708 Liabilities and Stockholders' Equity Current liabilities Accounts payable \$ 1,582 \$ 1,472 Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 37 62 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 458 16,869 16,804 Other long-term liabilities 17,92 -7 Total liabilities 37 36 Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,8	Goodwill	2,33	3 2,333		
Other long-term assets 731 536 Total assets 2 335,173 2 637,08 Liabilities and Stockholders' Equity Current liabilities *** 1,582 1,472 Accounts payable 13,366 8,651 Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 2,238 Total current liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 6,844 7,618 Term loan 18,669 16,004 Other long-term liabilities 179 - Total liabilities 37 3 Stockholders' equity 37 3 Stockholders' equity 482,865 467,147 Additional paid-in capital 482,865 467,147	Intangible assets, net	27	7 400		
Total assets \$ 235,173 \$ 263,708 Labilities and Stockholders' Equity Current liabilities Accounts payable \$ 1,562 \$ 1,472 Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 37 62 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 17,92 Other long-term liabilities 37 62 Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit	Right of use assets	8,07	5 8,976		
Liabilities and Stockholders' Equity Current liabilities Accounts payable \$ 1,582 \$ 1,472 Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 37 62 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Other long-term assets	73	1 536		
Current liabilities \$ 1,582 \$ 1,472 Accounts payable \$ 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilitities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 291,395 226,134	Total assets	\$ 235,17	3 \$ 263,708		
Accounts payable \$ 1,582 \$ 1,472 Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Other long-term liabilities 179 - Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Liabilities and Stockholders' Equity				
Accrued liabilities 13,366 8,651 Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Current liabilities				
Income taxes payable 147 94 Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Accounts payable	\$ 1,58	2 \$ 1,472		
Deferred revenue 163 71 Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Accrued liabilities	13,36	6 8,651		
Credit agreement, current 91 - Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Income taxes payable	14	7 94		
Current lease liabilities 2,201 2,238 Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Deferred revenue	16	3 71		
Total current liabilities 17,550 12,526 Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Credit agreement, current	g	1 -		
Deferred tax liability 37 62 Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Current lease liabilities	2,20	1 2,238		
Long-term lease liabilities 6,844 7,618 Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Total current liabilities	17,55	0 12,526		
Credit agreement 455 564 Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Deferred tax liability	3	7 62		
Term loan 16,869 16,804 Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Long-term lease liabilities	6,84	4 7,618		
Other long-term liabilities 179 - Total liabilities 41,934 37,574 Stockholders' equity 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Credit agreement	45	5 564		
Total liabilities 41,934 37,574 Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Term loan	16,86	9 16,804		
Stockholders' equity 37 36 Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Other long-term liabilities	17	9		
Common stock 37 36 Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Total liabilities	41,93	4 37,574		
Additional paid-in capital 482,885 467,147 Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Stockholders' equity				
Accumulated other comprehensive income 1,712 1,685 Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Common stock	3	7 36		
Accumulated deficit (291,395) (242,734) Total stockholders' equity 193,239 226,134	Additional paid-in capital	482,88	5 467,147		
Total stockholders' equity 193,239 226,134	·	1,71	2 1,685		
Total stockholders' equity 193,239 226,134	Accumulated deficit	(291,39	5) (242,734)		
	Total stockholders' equity	193,23	9 226,134		

Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change (in thousands) (Unaudited)

Three months ended December 31,

	 2021	2020	% Change	FX Impact %	Constant Currency % Change
United States	\$ 7,274	\$ 4,874	49.2%	-%	49.2%
International	\$ 6,434	\$ 4,956	29.8%	(1.1)%	30.9%
Total	\$ 13,708	\$ 9,830	39.5%	(0.5)%	40.0%
	 Twelve mo Decem	 			
	2021	2020	% Change	FX Impact %	Constant Currency % Change
United States	\$ 24,991	\$ 16,191	54.4%	-%	54.4%
International	\$ 23,425	\$ 16,542	41.6%	6.5%	35.1%
Total	\$ 48,416	\$ 32,733	47.9%	3.3%	44.6%